AFP and hepatocellular carcinoma: Although α-fetoprotein (AFP) was reported to be an independent surrogate end point for survival, which was evaluated together with the radiological response in sorafenib-treated HCC patients, serum AFP levels are not a pretreatment characteristic which can be used to predict responsiveness to sorafenib [40].